Efficacy and Functional Recovery After Switching From Paliperidone Palmitate Injection to Oral Antipsychotics in Schizophrenia

Other illness

• Comorbid psychiatric diagnoses other than schizophrenia;
• Severe physical diseases, intellectual disability, organic brain disorders, or mental disorders due to physical illnesses;
• History of psychoactive substance abuse (excluding tobacco) within the past 12 months, or significant suicidal/violent tendencies;
• Current or history of tardive dyskinesia (TD), neuroleptic malignant syndrome (NMS), or severe extrapyramidal symptoms (EPS);
• Treatment-resistant schizophrenia (failure of ≥2 adequate antipsychotic regimens of different compounds);
• Hypersensitivity or inefficacy to risperidone or paliperidone; 8. Pregnancy, lactation, planned pregnancy, or failure to use effective contraception during the study;
  • 9\. Other conditions deemed unsuitable by the investigator. \|

Lab values

• QTc interval \>450 ms (male) or \>460 ms (female);

• Outpatients or inpatients meeting DSM-5 diagnostic criteria forschizophrenia;
• Aged 18-65 years (inclusive), regardless of gender;
• Currently receiving first- or second-generation oral antipsychotics (excluding clozapine) with stable condition as assessed by the investigator, and PANSS total score ≤80 at screening and baseline;
• Signed informed consent by the patient and/or guardian;